

# Long non-coding RNAs in cancer: then, now and ahead

[www.butantan.gov.br](http://www.butantan.gov.br)

**Sergio Verjovski-Almeida**  
Laboratório de Ciclo Celular  
Instituto Butantan  
São Paulo, Brazil




Cancer Genomics



**FAPESP**  
60 YEARS  
1962 - 2022


# Number of papers per year in PubMed

## long non-coding RNAs





C.J. Brown et al., *Nature* 349: 38-44, 1991 ↑  
Xist lncRNA = inactive-X specific transcript

## long non-coding RNAs



↑ Human genome sequence  
International Human Genome Sequencing Consortium, *Nature* 409, 860 (2001)  
Venter J. C., et al., *Science* 291, 1304 (2001)

# Number of papers per year in PubMed





## The FAPESP-IICR Human Cancer Genome Project

A Program for Human Gene Discovery  
and Complete Sequence Compilation




### Total (all groups together)

Mitochondria	62,114	(5.34%)
rRNA	44,891	(3.86%)
Bacteria	53,384	(4.59%)
<b>Known Human Genes</b>	<b>203,569</b>	<b>(17.50%)</b>
<b>Unigene Contigs</b>	<b>263,930</b>	<b>(22.69%)</b>
Non-unigene ESTs	94,967	(8.16%)
Paralogs	7,914	(0.68%)
Non-Human Protein	11,080	(0.95%)
ESTs	32	(0.00%)
DNA	126	(0.01%)
Repeats	75,624	(6.50%)
<b>Nomatches</b>	<b>344,658</b>	<b>(29.63%)</b>
Human Protein	991	(0.09%)
<b>Total number of sequences</b>	<b>1,163,280</b>	


Last update: Fri May18 06:00:01 EST 2001

- E. Dias-Neto et al., *Proc. Natl. Acad. Sci. USA* 97: 3491-3496, 2000  
A. Camargo et al., *Proc. Natl. Acad. Sci. USA* 98: 12103-12108, 2001  
H. Brentani et al., *Proc. Natl. Acad. Sci. USA* 100: 13418-13423, 2003

## Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer



# Identification of the eukaryotic mammalian transcriptome complexity has redefined the concept of a gene



ENCODE – ENCyclopedia Of Dna Elements  
 Birney et al. 2007 *Nature* **447**, 799-816  
 Derrien et al., 2012 *Genome Res* **22**, 1775-1789



Nakaya et al., 2007 *Genome Biology* **8**, R43

# Custom designed oligo-microarray to probe the intronic lncRNA transcriptome in three different human tissue samples

**Genome mapping and expression analyses of human intronic noncoding RNAs reveal tissue-specific patterns and enrichment in genes related to regulation of transcription**


Helder I Nakaya, Paulo P Amaral, Rodrigo Louro, André Lopes, Angela A Fachel, Yuri B Moreira, Tarik A El-Jundi, Aline M da Silva, Eduardo M Reis and Sergio Verjovski-Almeida

*Genome Biology* 8: R43, 2007



**Most highly expressed intronic lncRNA transcripts map to the loci of protein-coding genes related to regulation of transcription**


# Examples of mechanisms of lncRNAs associated with cancers





# LncRNAs associated with hallmarks of cancer

LncRNAs contribute to the onset and progression of cancer



# What are the mechanisms of action of long noncoding RNAs?

**ANRASSF1** – an antisense lncRNA involved in the **inhibition of tumor suppressor RASSF1A** gene expression, thus **causing increased cell proliferation**  
*PLoS Genetics* 9(8): e1003705, 2013

**HIPSTR** – an antisense lncRNA that is involved in **regulation of the developmental program** in 8-cell and morula **human embryos**  
*Scientific Reports* 6: 32753, 2016

**Chromatin landscape** distinguishes the Genomic Loci of Hundreds of **Androgen-Receptor-Associated LincRNAs** From the Loci of Non-associated LincRNAs  
*Frontiers in Genetics* 9: 132, 2018

**PVT1** – **PVT1 lincRNA** is an overexpressed **oncogene that is associated with AR** in LNCaP prostate cancer cells. We provide first evidence that **PVT1 signals a genome-wide transcriptional repressive program of tumor suppressor protein-coding genes** in prostate cancer cells  
*Cell Communication and Signaling* 19: 5, 2021

# The Intronic Long Noncoding RNA *ANRASSF1* Recruits PRC2 to the *RASSF1A* Promoter, Reducing the Expression of *RASSF1A* and Increasing Cell Proliferation


Beckedorff et al. 2013, *PLoS Genetics* 9: e1003705

*RASSF1A* is an important tumor suppressor gene that is downregulated in prostate cancer.

We identified by RACE, by PCR and by RNA-seq

an unspliced 790 nt lncRNA, expressed in the antisense direction in the locus of *RASSF1*,

We named the antisense lncRNA as *ANRASSF1*




# The Intronic Long Noncoding RNA *ANRASSF1* Recruits PRC2 to the *RASSF1A* Promoter, Reducing the Expression of *RASSF1A* and Increasing Cell Proliferation




Beckedorff et al. 2013, *PLoS Genetics* 9: e1003705

***ANRASSF1* lncRNA overexpression inhibits tumor suppressor *RASSF1A* gene expression, thus causing increased cell proliferation**

***ANRASSF1* lncRNA interacts with PRC2 complex**



**and recruits PRC2 complex to the *RASSF1A* promoter**




**OPEN** *HIPSTR* and thousands of lncRNAs are heterogeneously expressed in human embryos, primordial germ cells and stable cell lines

Received: 04 July 2016  
Accepted: 11 August 2016  
Published: 08 September 2016

Dinar Yunusov<sup>1,2</sup>, Leticia Anderson<sup>1,2</sup>, Lucas Ferreira DaSilva<sup>1,2</sup>, Joanna Wysocka<sup>1</sup>, Toshihiko Ezashi<sup>1</sup>, R. Michael Roberts<sup>1,3</sup> & Sergio Vojtovski-Almeida<sup>1,2</sup>

*TFAP2A* encodes a TF known to be involved in various cancers including prostate cancer, where *TFAP2A* is downregulated

*HIPSTR* lncRNA is expressed from chr6:10404735–10408161 in the locus of protein-coding *TFAP2A* gene, in the opposite genomic strand




**OPEN** *HIPSTR* and thousands of lncRNAs are heterogeneously expressed in human embryos, primordial germ cells and stable cell lines



Received: 04 July 2016  
Accepted: 13 August 2016  
Published: 08 September 2016

Dinar Yunusov<sup>1,2</sup>, Leticia Anderson<sup>1,2</sup>, Lucas Ferreira DaSilva<sup>1,2</sup>, Joanna Wysocka<sup>1</sup>, Toshiko Ezashi<sup>1</sup>, R. Michael Roberts<sup>1,3</sup> & Sergio Verjovski-Almeida<sup>1,2</sup>

*HIPSTR* knockdown in HEK293 resulted in genome-wide differential expression of 380 genes located outside of the *TFAP2A* locus, of which 377 (~99.2%) were upregulated.

Gene Ontology (GO) analysis of these genes revealed their enrichment in “Developmental Process” and “Cell Differentiation” categories. These results suggest a repressive function for *HIPSTR* in HEK293 cells.






## What is the lincRNA complement of prostate cancer cells?


LNCaP cells treated for 24 h with 1 nM R1881 androgen or vehicle.

Poly(A)+RNA was extracted.

Stranded RNA libraries were prepared, and RNA-seq was obtained from two samples per LNCaP treatment: ~ 85 million mate pair reads per each of four samples, a total of 340 million paired-end reads.



A large number of lincRNAs are physically associated to the androgen receptor (AR)




RIP-Sequencing of lincRNAs  
co-immunoprecipitated with anti-AR antibody  
shows 619 lincRNAs (green)  
significantly enriched in the anti-AR fraction  
over IgG control


(FDR < 5% in DESEQ2)



**ARA-lincRNAs**  
map **closer to the neighbor**  
**protein-coding gene**  
than the NonA-lincRNAs




Protein coding genes in the vicinity of lincRNAs  
associated with AR  
are **enriched in a set of biological functions**




Chromatin topologically associating domains (TADs) of LNCaP that contain **ARA-lincRNAs** have a significantly higher content of a **given set of histone marks**, compared with TADs whose lincRNAs are not associated to AR


The identified high-ranked marks suggest that **ARA-lincRNAs** act as **enhancer RNAs**

All possible pairwise comparisons resulted in statistically significant differences ( $p$ -value < 0.05, t-test)



ARA-lincRNA expression correlates with that of the protein-coding gene neighbor





Modified from Tan M.H.E. et al. *Acta Pharm. Sinica* (2015) 36: 3–23

## Perspective


Hundreds of **lincRNAs** were identified that **interact with the Androgen Receptor (AR)** complex, and they are **candidates to regulate** the expression of protein-coding genes either in their vicinity or in the TAD where the lincRNA is expressed.

A number of interesting **protein-coding genes** known to be **involved in prostate cancer** were identified that **have an ARA-lincRNA** expressed in **their vicinity**.


These pairs are candidates for further studies on the possible mechanism of action of the lincRNA on the expression of the protein-coding gene neighbor.

# PVT1 lincRNA signals an androgen-dependent transcriptional repression program in prostate cancer cells

Videira et al., Cell Commun Signal (2021) 19: 5





Genes **de-repressed** by **PVT1 lincRNA knockdown** in androgen-stimulated LNCaP cells are **enriched in tumor suppressor** functions



# PVT1 lincRNA signals an androgen-dependent transcriptional repression program in prostate cancer cells

Videira et al., Cell Commun Signal (2021) 19: 5

The expression levels of **121 genes down-regulated by PVT1 lincRNA**, identified in our analysis, can **predict high-risk Prostate Adenocarcinoma tumors** in the TCGA database using a Random Forest machine-learning model (ROC AUC = 0.89).



We show that **PVT1 lincRNA signals** a genome-wide **transcriptional repression of protein-coding genes** in prostate cancer.

The **repressed gene set is enriched in tumor suppressor functions**, which may lie behind the known aggressive phenotype of tumors expressing high levels of PVT1 lincRNA oncogene.

# ASO and siRNA therapeutics that are approved by the FDA as of 2022

ASO and siRNA therapeutics that approved by the FDA.

Type	Drug	Mechanism	Target organ	Disease	Administration
<b>ASO</b>	Nusinersen (Spinraza, ASO-10-27)	Antisense, splicing modulation	Central nervous system	Spinal muscular atrophy	Intrathecal
	Fomivirsen (Vitravene)	Antisense	Eye	Cytomegalovirus Retinitis	Intravitreal
	Eteplirsen (Exondys 51)	Antisense, splicing modulation	Muscle	Duchenne muscular dystrophy	Intravenous
	Golodirsen (Vyondys 53, SRP-4053)	Antisense, splicing modulation	Muscle	Duchenne muscular dystrophy	Intravenous
	Viltolarsen (Viltepso, NS-065, NCNP-01)	Antisense, splicing modulation	Muscle	Duchenne muscular dystrophy	Intravenous
	Casimersen (Amondys 45)	Antisense, splicing modulation	Muscle	Duchenne muscular dystrophy	Intravenous
	Mipomersen (Kynamro)	Antisense	Liver	Familial hypercholesterolaemia	Subcutaneous
	Inotersen (Tegsedi)	Antisense	Liver	Hereditary transthyretin amyloidosis	Subcutaneous
	Volanesorsen (Waylivra)	Antisense	Liver	Familial chylomicronaemia syndrome	Subcutaneous
	<b>siRNA</b>	Patisiran (Onpattro)	RNA interference	Liver	Hereditary transthyretin amyloidosis
Givosiran (Givlaari)		RNA interference	Liver	Acute hepatic porphyria	Subcutaneous
Inclisiran (Leqvio, ALN-PCSsc)		RNA interference	Liver	Primary hypercholesterolaemia	Subcutaneous
Lumasiran (Oxlumo, ALN-GO1)		RNA interference	Liver	Primary hyperoxaluria	Subcutaneous

# Acknowledgments



## Lab. de Expressão Gênica em Eucariotos

**Sergio Verjovski-Almeida**  
**Maria Gabriela Berzoti Coelho**  
**Gabriel Nakanishi Fortes**  
**Fabio Nunes de Mello**  
**Thalles Souza Lopes**  
**David A. Morales-Vicente**  
**Alexandre Videira**

**Murilo S. Amaral**  
**Gilbert O. Silveira**  
**Daisy Woellner Santos**  
**Ana Carolina Tahira**  
**João V. M. Malvezzi**  
**Vinicius Mesel**

